Adds new patent global licence portfolio

RNS Number : 3626R

Tissue Regenix Group PLC

19 November 2012

 



19 November 2012

Tissue Regenix adds patent related to 'Acellular Arteries' to global exclusive licence portfolio

AV dialysis graft aimed at growing number of patients worldwide being treated for end-stage renal disease

York, 19 November 2012 - Tissue Regenix Group plc ('Tissue Regenix'), the regenerative medical devices company, has added a patent application related to 'Acellular Arteries'.  The patent is the latest in its portfolio granted through its worldwide exclusive licence from the University of Leeds.

The new 'Acellular Arteries' patent relates to the development of products to address some major indications, such as Arteriovenous ('AV') dialysis grafts and coronary artery bypass grafts ('CABG').

The AV dialysis graft product is aimed at patients being treated for end-stage renal disease ('ESRD'), a group that is growing at five times the rate of world population growth.¹  Currently there are estimated to be 820,000 ESRD patients in the EU and US, 70% of whom receive dialysis annually.²   An estimated 60% of AV grafts fail within the first year, something the TR product aims to  address.

Antony Odell, Managing Director of Tissue Regenix commented: "This patent relating to 'Acellular Arteries' is an important addition to our global exclusive licence portfolio. The AV dialysis graft product has the potential to address some of the issues associated end-stage renal disease, a growing problem worldwide.  Growth in the disease is being driven by the globally ageing population, the higher life‐expectancy of treated ESRD patients and increasing access of a generally younger patient population to treatment in countries in which access to date has been limited."

Since Tissue Regenix was established in 2006 to commercialise academic research in the field of tissue decellularisation, it has been licenced to a series of patent families, which comprise granted and pending patent applications.

-ENDS-

Notes to editors:

1.    http://ndt.oxfordjournals.org/content/17/12/2071.full

2.    Shire Regenerative Medicine 2012

For Further Information

Tissue Regenix Group plc:                                                           01904 435 176

Antony Odell

Newgate Communications

Alistair Kellie                                                                                    07801 234598

Andrew Adie                                                                                    07970 256512

Martin Greig                                                                                     07584 221513

About Tissue Regenix

Tissue Regenix (AIM: TRX) was formed in 2006 when the company was spun out from the University of Leeds, where Professor Eileen Ingham and Professor John Fisher had produced ground breaking work in the field of tissue engineering and regenerative medicine. 

At the heart of Tissue Regenix is its patented dCELL® process which removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body.  Since 2006, Tissue Regenix has successfully raised money to commercialise the Intellectual Property rights of the technology developed by its research partners in Leeds, Brazil and the NHS. 

Tissue Regenix's development plans are structured around four key product areas: Vascular, Cardiac, Woundcare and Orthopaedics. In 2010 the company was floated and admitted to the Alternative Investment Market (AIM).

 

END

 

 

NRABFBITMBBBBRT